caa a22 4500 465738958 CHVBK 20180323111803.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF02244614 doi (NATIONALLICENCE)springer-10.1007/BF02244614 Atypical neuroleptics suppress dopaminergic behavioral supersensitivity [Elektronische Daten] [Corinna Schremmer, Rudolf Morgenstern, Heidrun Fink, Tilmann Ott] Seven days after bilateral 6-OHDA denervation of the nucleus accumbens locomotor activity was recorded in rats. 6-OHDA lesion strongly enhanced hypermotility induced by apomorphine (1.0 mg/kg IP) as a sign of behavioral dopaminergic supersensitivity. The potency of the classical neuroleptic haloperidol (0.03-0.25 mg/kg IP) to antagonize apomorphine-induced hypermotility was reduced in 6-OHDA-pretreated rats. The atypical neuroleptics sulpiride (5.0-20.0 mg/kg IP), thioridazine (1.0-5.25 mg/kg IP) and clozapine (0.5-2.0 mg/kg IP) and the 5-HT antagonists cyproheptadine (0.2 mg/kg IP) and ritanserin (0.01 mg/kg IP) suppressed the augmented apomorphine response in 6-OHDA-lesioned animals to the level of the apomorphine effect in controls. It is concluded that the model of denervation supersensitivity is capable of differentiating typical and atypical neuroleptics. The abolition of the 6-OHDA-induced increase of the apomorphine hypermotility by the atypical neuroleptics cannot be explained solely by postsynaptic dopamine receptor antagonism. Serotonergic mechanism may be involved in this action. Springer-Verlag, 1990 6-Hydroxydopamine lesion nationallicence Nucleus accumbens nationallicence Dopaminergic supersensitivity nationallicence Locomotor activity nationallicence Atypical neuroleptics nationallicence Serotonin antagonists nationallicence Schremmer Corinna Institute of Pharmacology and Toxicology of Charité, Humboldt University at Berlin, PF 140, DDR-1040, Berlin, German Democratic Republic aut Morgenstern Rudolf Institute of Pharmacology and Toxicology of Charité, Humboldt University at Berlin, PF 140, DDR-1040, Berlin, German Democratic Republic aut Fink Heidrun Institute of Pharmacology and Toxicology of Charité, Humboldt University at Berlin, PF 140, DDR-1040, Berlin, German Democratic Republic aut Ott Tilmann Institute of Pharmacology and Toxicology of Charité, Humboldt University at Berlin, PF 140, DDR-1040, Berlin, German Democratic Republic aut Psychopharmacology Springer-Verlag 100/3(1990-03-01), 399-403 0033-3158 100:3<399 1990 100 213 https://doi.org/10.1007/BF02244614 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244614 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Schremmer Corinna Institute of Pharmacology and Toxicology of Charité, Humboldt University at Berlin, PF 140, DDR-1040, Berlin, German Democratic Republic aut NATIONALLICENCE 700 1- Morgenstern Rudolf Institute of Pharmacology and Toxicology of Charité, Humboldt University at Berlin, PF 140, DDR-1040, Berlin, German Democratic Republic aut NATIONALLICENCE 700 1- Fink Heidrun Institute of Pharmacology and Toxicology of Charité, Humboldt University at Berlin, PF 140, DDR-1040, Berlin, German Democratic Republic aut NATIONALLICENCE 700 1- Ott Tilmann Institute of Pharmacology and Toxicology of Charité, Humboldt University at Berlin, PF 140, DDR-1040, Berlin, German Democratic Republic aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 100/3(1990-03-01), 399-403 0033-3158 100:3<399 1990 100 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer